Table 1.
Baseline characteristics of triglyceride glucose index < 1.79 and triglyceride glucose index ≥ 1.79, n (%)
|
Variables
|
Overall (n = 300)
|
Low TyG index (n = 164)
|
High TyG index (n = 136)
|
P value
|
| BMI, kg/m2, mean ± SD | 22.71 ± 2.93 | 22.12 ± 2.86 | 23.42 ± 2.86 | < 0.001a |
| Fasting glucose, mg/dL, mean ± SD | 6.53 ± 1.77 | 5.20 ± 1.02 | 8.13 ± 0.99 | < 0.001a |
| Fasting triglycerides, mg/dL, mean ± SD | 1.74 ± 0.41 | 1.45 ± 0.27 | 2.09 ± 0.23 | < 0.001a |
| Tyg index, mean ± SD | 1.67 ± 0.54 | 1.29 ± 0.43 | 2.12 ± 0.22 | < 0.001a |
| Age, years | 0.514 | |||
| < 60 | 135 (45.00) | 71 (43.29) | 64 (47.06) | |
| ≥ 60 | 165 (55.00) | 93 (56.71) | 72 (52.94) | |
| Sex | 0.833 | |||
| Female | 152 (50.67) | 84 (51.22) | 68 (50.00) | |
| Male | 148 (49.33) | 80 (48.78) | 68 (50.00) | |
| Drinking history | 0.387 | |||
| No | 204 (68.00) | 115 (64.02) | 89 (65.44) | |
| Yes | 92 (32.00) | 49 (29.88) | 47 (34.56) | |
| Smoking history | 0.859 | |||
| No | 208 (69.33) | 113 (68.90) | 95 (69.85) | |
| Yes | 92 (30.67) | 51 (31.10) | 41 (30.15) | |
| ECOG | 0.583 | |||
| 0 | 198 (66.00) | 106 (64.63) | 92 (67.65) | |
| 1 | 102 (34.00) | 58 (35.37) | 44 (32.35) | |
| Site | 0.054 | |||
| Stomach | 150 (50.17) | 74 (45.12) | 64 (47.06) | |
| Gastric and esophageal binding | 149 (49.83) | 90 (54.88) | 72 (52.94) | |
| Histological | 0.189 | |||
| Adenocarcinoma | 216 (72.00) | 113 (68.90) | 103 (75.74) | |
| Other | 84 (28.00) | 51 (31.10) | 33 (24.26) | |
| CEA, ng/mL | 0.188 | |||
| < 3 | 90 (30.00) | 44 (26.81) | 46 (33.82) | |
| ≥ 3 | 210 (72.00) | 120 (73.17) | 90 (66.18) | |
| AFP, ng/mL | 0.169 | |||
| < 15 | 253 (84.33) | 134 (81.71) | 119 (87.50) | |
| ≥ 15 | 47 (15.67) | 30 (18.29) | 17 (12.50) | |
| CA-199, ng/mL | 0.071 | |||
| < 37 | 184 (61.33) | 93 (56.71) | 91 (66.91) | |
| ≥ 37 | 116 (38.67) | 71 (43.29) | 45 (33.09) | |
| Liver metastasis | 0.798 | |||
| No | 194 (64.67) | 105 (70.12) | 89 (65.44) | |
| Yes | 106 (35.33) | 59 (35.98) | 47 (34.56) | |
| Peritoneal metastasis | 0.423 | |||
| No | 241 (80.33) | 129 (78.66) | 112 (82.35) | |
| Yes | 59 (19.67) | 35 (21.34) | 24 (17.65) | |
| EBV status | 0.390 | |||
| No-infect | 253 (84.33) | 141 (85.98) | 112 (82.35) | |
| Infect | 47 (15.67) | 23 (14.02) | 24 (17.65) | |
| PD-L1 expression | 0.059 | |||
| CPS < 5 | 51 (17.00) | 34 (20.73) | 17 (12.50) | |
| CPS ≥ 5 | 249 (83.00) | 130 (79.27) | 119 (87.50) | |
| MMR status | 0.125 | |||
| pMMR | 289 (96.33) | 155 (94.51) | 134 (98.53) | |
| dMMR | 11 (3.67) | 9 (5.49) | 2 (1.47) |
a
P < 0.05.
TyG: Triglyceride glucose; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; CEA: Carcinoembryonic-antigen; AFP: Alpha-fetoprotein: CA-199: Carbohydrate antigen 199; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair.